Surveillance of antimicrobial resistance is critical in guiding national management guidelines to ensure appropriate treatment.
The M. genitalium antimicrobial resistance surveillance (MARS) pilot was established to assess the feasibility of conducting sentinel surveillance of antimicrobial resistance in M. genitalium from specimens collected in sentinel sexual health clinics across England. Subsequent survey rounds and continued M. genitalium surveillance through MARS will provide a rich resource for informing future updates to management guidelines in the UK.
For queries relating to MARS, please contact: email@example.com
Cases of treatment failure to second-line therapeutics, such as moxifloxacin, should be reported to Public Health England (PHE) using the HIV and STI web portal